| Recruiting | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors NCT07090499 | Pfizer | Phase 1 |
| Terminated | A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and NCT05551117 | MacroGenics | Phase 2 |
| Unknown | Time to Treatment and Disease-free Survival of Patients With High-risk Head-neck Cutaneous Squamous Cell Carci NCT05845632 | Maastricht University Medical Center | — |
| Unknown | Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma NCT03799744 | Institut Català d'Oncologia | Phase 1 |
| Completed | Smoking Tobacco Cessation Integrated Program of Patients Treated for the Head and the Neck Cancer NCT03788785 | Assistance Publique - Hôpitaux de Paris | N/A |
| Terminated | A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With C NCT03735290 | Mendus | Phase 1 |
| Completed | Adjuvant De-Escalated Radiation + Adjuvant Nivolumab for Intermediate-High Risk P16+ Oropharynx Cancer NCT03715946 | Robert L. Ferris, MD, PhD | Phase 2 |
| Completed | ctDNA as a Biomarker for Treatment Response in HNSCC NCT03540563 | The Netherlands Cancer Institute | N/A |
| Completed | A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck NCT03620123 | AIO-Studien-gGmbH | Phase 2 |
| Active Not Recruiting | Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors NCT03485209 | Seagen, a wholly owned subsidiary of Pfizer | Phase 2 |
| Completed | Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors NCT03509012 | AstraZeneca | Phase 1 |
| Unknown | Biomarker-based Study in R/M SCCHN NCT03088059 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Unknown | Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC NCT03291002 | CureVac | Phase 1 |
| Completed | NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head a NCT03109158 | NanoCarrier Co., Ltd. | Phase 1 / Phase 2 |
| Terminated | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors NCT02952989 | Seagen Inc. | Phase 1 |
| Completed | Bioimmunoradiotherapy (Cetuximab/RT/Avelumab) NCT02938273 | The Netherlands Cancer Institute | Phase 1 |
| Terminated | Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous C NCT02822482 | UNICANCER | Phase 1 / Phase 2 |
| Completed | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors NCT02658214 | AstraZeneca | Phase 1 |
| Unknown | Concurrent Chemoradiotherapy(CRT) in Locally Advanced(LA) SCCHN vs Cetuximab With Radiotherapy (RT) After Neoa NCT02753140 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Phase 2 |
| Completed | Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of t NCT02289209 | Dan Zandberg | Phase 2 |
| Completed | Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC NCT02585973 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Terminated | Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma NCT02277184 | Julie E. Bauman, MD, MPH | Phase 1 |
| Completed | Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) NCT02277197 | James J Lee | Phase 1 |
| Completed | Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head NCT02383966 | Merck KGaA, Darmstadt, Germany | Phase 3 |
| Terminated | Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatm NCT02438995 | Northwell Health | Phase 1 |
| Completed | Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma NCT02296684 | Washington University School of Medicine | Phase 2 |
| Completed | Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and NCT02113878 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | PD 0332991 and Cetuximab in Patients With Incurable SCCHN NCT02101034 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Completed | State of the Art Photon Therapy Versus Particle Therapy for Recurrent Head & Neck Tumors; a Planning Study NCT02242916 | Maastricht Radiation Oncology | — |
| Completed | CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer NCT02052960 | Glycotope GmbH | Phase 2 |
| Completed | Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cel NCT01836029 | Celgene | Phase 2 |
| Terminated | A Prospective Study of Prophylactic Gastrostomy in Head and Neck Cancer Patients Undergoing Chemoradiotherapy NCT01876693 | Mahidol University | N/A |
| Completed | Neoadjuvant Afatinib Window Study in Squamous Cell Carcinoma of the Head and Neck NCT01538381 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Terminated | Phase III Trial of PET/CT vs. CTSurveilance for Head and Neck Cancer NCT02655068 | University of Pittsburgh | Phase 3 |
| Terminated | A Study to Evaluate the Safety and Efficacy of Amphinex Induced PCI of Bleomycin for Recurrent Head and Neck C NCT01606566 | PCI Biotech AS | Phase 2 |
| Terminated | Safety and Efficacy of Radiation/Cetuximab Plus EGFR Antisense DNA for Head and Neck Squamous Cell Carcinoma NCT00903461 | University of Pittsburgh | Phase 1 |
| Completed | Research of Biomarkers of Activity and Efficacy of BIBW2992 in Untreated Non-metastatic HNSCC Patients NCT01415674 | UNICANCER | Phase 2 |
| Completed | Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer NCT01588431 | The University of Texas Health Science Center at San Antonio | Phase 2 |
| Completed | Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy NCT01417936 | Symphogen A/S | Phase 2 |
| Completed | A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab NCT01307267 | Pfizer | Phase 1 |
| Completed | A Post Marketing Surveillance Study of Cetuximab in Patients With Squamous Cell Carcinoma of Head and Neck (SC NCT01080066 | Merck KGaA, Darmstadt, Germany | — |
| Completed | A Phase 1 Study in Participants With Advanced Cancer NCT01115790 | Eli Lilly and Company | Phase 1 |
| Unknown | Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer NCT00957086 | National Cancer Centre, Singapore | Phase 3 |
| Terminated | Treatment of Advanced Head and Neck Cancer NCT00982696 | Milton S. Hershey Medical Center | Phase 2 |
| Terminated | Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and N NCT00412776 | Sesen Bio, Inc. | Phase 2 / Phase 3 |